Islamabad asks India to provide additional evidence in 26/11 case
Pakistan on Thursday sought more evidence from India in connection with Mumbai attack case for the early completion of the Mumbai attack trial in which LeT operations commander Zaki-ur Rehman Lakhvi and six others are accused.
Addressing the weekly media briefing here, foreign office spokesman Nafees Zakariya said that Pakistan had written a letter to India in this regard, however, no response has been received from the other side yet. “Pakistan intends to resolve all outstanding issues with India through dialogue. We are ready to hold composite dialogue with India,” he added. Asked about threats against Pakistani artists in India by extremists, he said there are many other people in India who welcome and support artists and promote people-to-people exchanges between the two countries. “Both India and Pakistan agree that atmospherics should be improved and people-to-people contacts always help,” Mr Zakaria said.
He said religious tourism is part of such efforts and Pakistan has been encouraging it. Mr Zakaria also said that influential US Senator John McCain would shortly visit Pakistan and hold important talks on various issues.
Pakistan arrested seven Lashkar-e-Tayyaba-linked militants, including Lakhvi, for their role in the 2008 Mumbai attack in which 166 people were killed.
Mumbai attack mastermind Lakhvi, Abdul Wajid, Mazhar Iqbal, Hamad Amin Sadiq, Shahid Jameel Riaz, Jamil Ahmed and Younis Anjum are accused of abatement to murder, attempted murder, planning and executing the Mumbai attack.
Lakhvi is living at an undisclosed location after he got released from jail on bail a year ago. The other six suspects are in Adiala Jail Rawalpindi. The case has been going on in the country for more than six years. India has been urging Pakistan to complete the trial at the earliest. It has said that enough evidence has been shared with Islamabad to prosecute the accused. However, Pakistani officials say India has not provided enough evidence needed to successfully complete the trial.